Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours By Ogkologos - March 2, 2026 90 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PYNNACLE study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR How Clinical Trials Can Lead to Life-Saving Treatment: The TAPUR Trial... October 12, 2023 Substantial and Durable Overall and Intracranial Activity of Trastuzumab Deruxtecan in... September 27, 2024 Breast Cancer Survivors Are Still Underrepresented At Victoria’s Secret February 1, 2022 Osimertinib Improves Survival in Advanced Lung Cancer with EGFR Mutations December 12, 2019 Load more HOT NEWS Women Over Age 65 Years with Pathogenic Variants in Cancer Predisposition... Toripalimab Becomes First Immunotherapy Drug Approved for Nasopharyngeal Cancer Coping With the Difficult Times of Cancer Survivorship Through My “Bucket... Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate...
